The assay is fast and simple and has already shown clinical utility, although its interpretation may be limited by reference ...

The MHRA has approved Siiltibcy, a new skin test that uses recombinant proteins to more accurately detect tuberculosis in ...

More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs. | More ...

An artificial intelligence model predicts how brain immune cells react to RNA and DNA nanoparticles, helping scientists design safer and more effective nucleic acid therapies faster.

New services enable early assessment of compound safety and neurotoxic risk in drug discovery.

CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...

Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC− Supports the planned Phase 1 cohort of ...

Cellectricon broadens discovery capabilities with launch of Neurotoxicity Testing Services: Molndal, Sweden Saturday, November 1, 2025, 11:00 Hrs [IST] Cellectricon, a services pr ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to ...

As chronic liver disease becomes more widespread, researchers at Science Tokyo have developed a lab-grown organoid that ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

Researchers found that combining regular exercise with omega-3 supplements can make a big difference for oral health. The duo ...